Comparative Pharmacology
Head-to-head clinical analysis: ALFENTANIL versus SUBLIMAZE PRESERVATIVE FREE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ALFENTANIL versus SUBLIMAZE PRESERVATIVE FREE.
ALFENTANIL vs SUBLIMAZE PRESERVATIVE FREE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Alfentanil is a potent, short-acting synthetic opioid analgesic that primarily acts as a mu-opioid receptor agonist. It binds to mu-opioid receptors in the central nervous system, leading to G-protein coupled activation of inwardly rectifying potassium channels and inhibition of voltage-gated calcium channels, resulting in hyperpolarization and reduced neurotransmitter release. This produces analgesia, sedation, and respiratory depression.
Fentanyl is a potent synthetic opioid agonist with primary action at the mu-opioid receptor. It induces analgesia, sedation, and respiratory depression by activating G-protein-coupled receptors that inhibit adenylyl cyclase, reduce cAMP production, and modulate ion channels (e.g., potassium efflux, calcium influx).
Initial IV bolus of 5-20 mcg/kg; maintenance infusion of 0.5-1.5 mcg/kg/min; incremental boluses of 5-10 mcg/kg as needed. Induction of anesthesia: 50-100 mcg/kg IV.
IV: 0.5-2 mcg/kg bolus, may repeat q2-4h; or 0.5-1 mcg/kg/h infusion; IM: 0.5-2 mcg/kg q1-2h prn.
None Documented
None Documented
Clinical Note
moderateAlfentanil + Torasemide
"The risk or severity of adverse effects can be increased when Alfentanil is combined with Torasemide."
Clinical Note
moderateAlfentanil + Etacrynic acid
"The risk or severity of adverse effects can be increased when Alfentanil is combined with Etacrynic acid."
Clinical Note
moderateAlfentanil + Furosemide
"The risk or severity of adverse effects can be increased when Alfentanil is combined with Furosemide."
Clinical Note
moderateAlfentanil + Bumetanide
Terminal elimination half-life: 90–111 minutes (1.5–1.85 hours). Clinically, context-sensitive half-time is short (~40 min after 3-hour infusion) due to rapid redistribution and metabolism.
Terminal elimination half-life is 3-7 hours (mean 4.5 h) after IV administration, but may be prolonged (up to 12-15 h) in elderly, hepatic impairment, or after prolonged infusion due to redistribution.
Primarily hepatic metabolism via CYP3A4; <1% excreted unchanged in urine; metabolites (mainly noralfentanil) excreted renally. Biliary/fecal excretion of metabolites accounts for ~30%.
Primarily renal: fentanyl and its metabolites are excreted in urine (~75%) and feces (~9%). Less than 10% excreted unchanged.
Category C
Category C
Opioid Analgesic
Opioid Analgesic
"The risk or severity of adverse effects can be increased when Alfentanil is combined with Bumetanide."